Publications
Publications
Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy
Ramdial J, Chan KH, Sanchez Petitto G, Valdez B, Andersson BS, Nieto Y. Bone Marrow Transplant. 2023 Jun;58(6):635-638. doi: 10.1038/s41409-023-01964-y. Epub 2023 Mar 25. PMID: 36966213.
Acute Lymphoblastic Leukemia (ALL)
Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia
Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI; Acute Leukemia Committee of the CIBMTR. Biol Blood Marrow Transplant. 2018 Apr;24(4):726-733. doi: 10.1016/j.bbmt.2017.11.025. Epub 2017 Dec 25. PMID: 29197676; PMCID: PMC5902420.
Busulfan Plus Melphalan versus Melphalan Alone Conditioning Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: An Open-label, Randomized Phase III Trial
Bashir Q, Thall PF, Fox, Milton DR, Fox PS, Kawedia JD, Kebriaei P. Published in final edited form as: Lancet Haematol. 2019 May; 6(5): e266–e275. doi:10.1016/S2352-3026(19)30023-7.
Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT
Berger K, Schopohl D, Rieger C, Ostermann H. Support Care Cancer. 2015 Dec;23(12):3447-54. doi:
10.1007/s00520-015-2695-8. Epub 2015 Mar 17. PMID: 25773673; PMCID: PMC4624833.
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia
Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J,
Champlin RE. Biol Blood Marrow Transplant. 2002;8(9):477-85. doi:
10.1053/bbmt.2002.v8.pm12374452. PMID: 12374452.
Autologous transplantation for relapsed non-Hodgkin’s lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience
Escalón MP, Stefanovic A, Venkatraman A, Pereira D, Santos ES, Goodman M, Byrnes JJ, Fernandez HF. Bone Marrow Transplant. 2009 Jul;44(2):89-96. doi: 10.1038/bmt.2008.429. Epub 2009 Jan 26. PMID: 19169287.
Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience
Gayoso, J., Balsalobre, P., Pascual, M. et al. Bone Marrow Transplant 51, 1307–1312 (2016).